Beam Therapeutics (BEAM) Shares Outstanding (Diluted Average) (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $103.3 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $103.3 million, up 17.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.3 million (up 17.38% YoY), and the FY2025 annual result was $98.9 million, up 20.16% from the prior year.
• Shares Outstanding (Diluted Average) grew to $103.3 million in Q1 2026 per BEAM's latest filing, from $98.9 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $103.3 million in Q1 2026 and troughed at $68.7 million in Q1 2022.
• A 5-year average of $82.2 million and a median of $81.7 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) increased 5.2% in 2023, then gained 24.38% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $70.0 million in 2022, then grew by 10.19% to $77.2 million in 2023, then increased by 6.69% to $82.3 million in 2024, then increased by 20.16% to $98.9 million in 2025, then advanced by 4.4% to $103.3 million in 2026.
• Business Quant data shows BEAM's Shares Outstanding (Diluted Average) at $103.3 million in Q1 2026, $98.9 million in Q4 2025, and $97.6 million in Q3 2025.